Sistemik İmmün İnflamasyon İndeksi Diffüz Büyük B Hücreli Lenfoma Hastalarında Sağkalımı Öngörebilir Mi?

Öz

Amaç: Sistemik immün inflamasyon indeksi, birçok malign tümörde kullanılan yeni bir prognostik biyobelirteçtir. Bu çalışmanın amacı, Diffüz Büyük B Hücreli Lenfoma hastalarında sistemik immün inflamasyon indeksi ile prognoz arasındaki ilişkiyi belirlemektir. Gereç ve Yöntem: Çalışmaya Diffüz Büyük B Hücreli Lenfoma tanılı 101 hasta dahil edildi. Sağkalımı öngören optimum sistemik immün inflamasyon indeksi kesme değerini saptamak için receiver operating charecteristic curve analizi kullanıldı. Bulgular: Receiver operating charecteristic curve analizi ile sistemik immün inflamasyon indeksi kesme değeri 500 saptandı. Sistemik immün inflamasyon indeksi ≤ 500 ve sistemik immün inflamasyon indeksi >500 grupları arasında progresyonsuz sağkalım ve genel sağkalım açısından istatistiksel olarak anlamlı fark yoktu. Ancak sistemik immün inflamasyon indeksi ≤ 500 olan hastalarda mortalite riski anlamlı olarak yüksekti (p:0,017). Sistemik immün inflamasyon indeksi ile laktat dehidrogenaz, yaş, R-IPI risk grupları, ECOG performans durumu ve hastalık evresi arasında anlamlı bir ilişki yoktu. Sonuç: Çalışmamızın sonuçları, Diffüz Büyük B Hücreli Lenfoma hastalarında sistemik immün inflamasyon indeksi ile sağkalım arasında bir ilişki olmadığını göstermiştir. Sistemik immün inflamasyon indeksi ve DBBHL arasındaki ilişkiyi araştırmak için daha büyük prospektif çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

• Diffüz büyük B hücreli lenfoma
• Lenfosit
• Nötrofil
• Platelet
• Sağkalım
• Sistemik immün inflamasyon inde

Does Systemic Immune Inflammation Index Predicts Survival In Diffuse Large B Cell Lymphoma Patients?

Öz

Objective: The systemic immune inflammation index has been considered a novel prognostic biomarker in several malignant tumors. The aim of the current study was to determine the association between the systemic immune inflammation index and prognosis of patients with Diffuse Large B Cell Lymphoma. Material and Method: The study included 101 patients diagnosed diffuse large B cell lymphoma. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cut-off value of the systemic immune inflammation index for predicting survival. Results: The results of ROC curve analysis showed a cut-off value for the systemic immune inflammation index of 500. No statistically significant difference was determined between the groups with systemic immune inflammation index ≤ 500 and >500 groups in respect of overall-survival and progression-free survival. The mortality risk was determined to be significantly higher in patients with systemic immune inflammation index ≤ 500 (p:0.017). There was no significant relationship between the systemic immune inflammation index values and lactat dehydrogenase, age, R-IPI risk groups,ECOG performance status, and disease stage. Conclusion: The results of this study demonstrated that there is no association between the systemic immune inflammation index and survival in patients with diffuse large B cell lymphoma. Larger prospective studies are needed to investigate the association between the systemic immune inflammation index and Diffuse Large B Cell Lymphoma.

Anahtar Kelimeler

• Diffuse large B cell lymphoma
• systemic immun inflamation index
• platelet
• neutrophil
• lymphocyte
• survival

Kaynakça

1. Wu X-B, Hou S-L, Liu H. Systemic immune inflammation index, ratio of lymphocytes to monocytes, lactate dehydrogenase and prognosis of diffuse large B-cell lymphoma patients. World Journal of Clinical Cases 2021;9(32):9825.
2. Liu T, Ye F, Li Y, Liu A. Comparison and exploration of the prognostic value of the advanced lung cancer inflammation index, prognostic nutritional index, and systemic immune-inflammation index in newly diagnosed diffuse large B-cell lymphoma. Annals of Palliative Medicine 2021;10(9):9650-9659.
3. Wang Z, Zhang J, Luo S, Zhao X. Prognostic significance of systemic immune-inflammation index in patients with diffuse large B-cell lymphoma. Frontiers in Oncology 2021;11:655259.
4. Gupta T, Nayak P, Baviskar Y, et al. Systemic inflammatory biomarkers in primary central nervous system lymphoma versus high-grade glioma: exploratory, comparative and correlative analysis. CNS oncology 2022;11(02):CNS83.
5. Huang H, Liu Q, Zhu L, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Scientific reports 2019;9(1):1-9.
6. Fest J, Ruiter R, Mulder M, et al. The systemic immune-inflammation index is associated with an increased risk of incident cancer—A population-based cohort study. International Journal of Cancer 2020;146(3):692-698.
7. Raffetti E, Donato F, Castelnuovo F, et al. The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study. Journal of translational medicine 2015;13:1-8.
8. Wu J, Zhu H, Zhang Q, et al. Nomogram based on the systemic immune-inflammation index for predicting the prognosis of diffuse large B-Cell lymphoma. Asia-Pacific Journal of Clinical Oncology 2022.

9. Schietroma M, Romano L, Schiavi D, et al. Systemic inflammation response index (SIRI) as predictor of anastomotic leakage after total gastrectomy for gastric cancer. Surgical Oncology 2022;43:101791.
10. Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratislavske lekarske listy 2001;102(1):5-14.
11. Walzik D, Joisten N, Zacher J, Zimmer P. Transferring clinically established immune inflammation markers into exercise physiology: focus on neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and systemic immune-inflammation index. European Journal of Applied Physiology 2021;121(7):1803-1814.
12. Zarbock A, Polanowska-Grabowska RK, Ley K. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood reviews 2007;21(2):99-111.
13. Hu B, Yang X-R, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clinical Cancer Research 2014;20(23):6212-6222.
14. Yan M, Jurasz P. The role of platelets in the tumor microenvironment: from solid tumors to leukemia. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 2016;1863(3):392-400.
15. Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. Journal of Cancer 2018;9(18):3295.
16. Li S, Xia Z, Cao J, et al. Proposed new prognostic model using the systemic immune-inflammation index for primary central nervous system lymphoma: A prospective-retrospective multicohort analysis. Frontiers in Immunology 2022;13.
17. Zhong J-H, Huang D-H, Chen Z-Y. Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis. Oncotarget 2017;8(43):75381.
18. Yang J, Guo X, Hao J, Dong Y, Zhang T, Ma X. The prognostic value of blood-based biomarkers in patients with testicular diffuse large B-cell lymphoma. Frontiers in Oncology 2019;9:1392.
19. Goto H, Tsurumi H, Takemura M, et al. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index. Journal of cancer research and clinical oncology 2005;131:73-79.
20. Goto N, Tsurumi H, Takemura M, et al. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma. European journal of haematology 2006;77(3):217-225.